	US 11,931,406 B2
	Flavivirus vaccine
Patrick Baumhof, Tübingen (DE); Wolfgang Grosse, Tübingen (DE); Edith Jasny, Tübingen (DE); Thomas Kramps, Tübingen (DE); Daniel Voss, Tübingen (DE); Julia Dannenmaier, Tübingen (DE); Valérie Lecouturier, Chazay d'Azergues (FR); and Yves Girerd-Chambaz, Messimy (FR)
Assigned to CureVac SE, Tübingen (DE); and Sanofi Pasteur, Lyons (FR)
Appl. No. 16/772,131
Filed by CureVac SE, Tübingen (DE); and Sanofi Pasteur, Lyons (FR)
PCT Filed Dec. 12, 2018, PCT No. PCT/EP2018/084607 § 371(c)(1), (2) Date Jun. 11, 2020, PCT Pub. No. WO2019/115635, PCT Pub. Date Jun. 20, 2019.
Claims priority of application No. 17207141 (EP), filed on Dec. 13, 2017.
Prior Publication US 2021/0069315 A1, Mar. 11, 2021
Int. Cl. A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); A61K 2039/53 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6031 (2013.01); C12N 2770/24134 (2013.01)]

20 Claims

1. A pharmaceutical formulation comprising RNA formulated in a lipid nanoparticle (LNP), said RNA comprising

a) at least one coding region encoding at least one polypeptide comprising a flavivirus premembrane protein (prM) and a flavivirus envelope protein (E), wherein the at least one coding region comprises a nucleic acid sequence at least 95% identical to the coding sequence of SEQ ID NO: 2630, and

b) an untranslated region (UTR) comprising at least one heterologous UTR element,

wherein the flavivirus a dengue virus,

wherein said LNP comprises: (i) at least one cationic lipid; (ii) a neutral lipid; (iii) a sterol; and (iv) a PEG-lipid.